New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
07:46 EDTSLXP, RDHLSalix, RedHill Biopharma announce exclusive license agreement for RHB-106
Salix Pharmaceuticals (SLXP) and RedHill Biopharma (RDHL) announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. Financial terms of the transaction include an upfront payment of $7M and $5M in subsequent milestone payments to RedHill. Salix also has agreed to pay RedHill tiered royalties on net sales, ranging from low single-digit up to low double-digits. Under the worldwide license agreement, the parties also agreed on potential strategic collaboration with regard to certain other Salix products in specific territories.
News For SLXP;RDHL From The Last 14 Days
Check below for free stories on SLXP;RDHL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
08:31 EDTRDHLRedHill Biopharma expands RHB-105 Phase 2 ERADICATE study
Subscribe for More Information
August 20, 2014
17:59 EDTSLXPAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTSLXPAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTSLXPAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTSLXPAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTSLXPPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:04 EDTSLXPSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTSLXPOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTSLXPAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTSLXPSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:28 EDTSLXPJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
13:15 EDTSLXPSalix options active after WSJ report of Allergan approach
Subscribe for More Information
13:13 EDTSLXPAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTSLXPSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTSLXPAllergan approached Salix about takeover, WSJ reports
07:02 EDTSLXPSalix announces early termination of HSR Waiting Period for Cosmo transaction
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use